Jade Biosciences reports $336M cash; outlines 2026 pipeline milestones including JADE101 Phase 2

Jade Biosciences, Inc.

Cash, cash equivalents and investments ~$336M as of Dec 31, 2025; funds operations into H1 2028.
JADE101 Phase 1 interim data expected H1 2026; Phase 2 in IgAN to start mid-2026 with preliminary data in 2027.
JADE201 (anti-BAFF-R) first-in-human study in RA expected Q2 2026; interim data in 2027.
JADE301 nominated; preclinical; Phase 1 expected H1 2027; details disclosed H2 2026.
Company to present at J.P. Morgan Healthcare Conference on Jan 15, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.